Generating orally active galanin analogues with analgesic activities

Area of Science:

• Neuroscience
• Pharmacology
• Medicinal Chemistry

Background:

• Galanin is an endogenous neuropeptide with known anticonvulsant and analgesic properties.
• These effects are mediated by galanin receptors in the central and peripheral nervous systems.
• Previous modifications yielded analogues effective via intraperitoneal administration but not oral.

Purpose of the Study:

• To develop orally active galanin analogues.
• To enhance the therapeutic potential of galanin-based compounds for pain and seizure disorders.
• To investigate the analgesic efficacy of a novel orally active galanin analogue.

Main Methods:

• Redesign of the lead compound Gal-B2 (NAX 5055) using central truncation, D-amino acids, and backbone spacers.
• Synthesis of analogue D-Gal(7-Ahp)-B2 incorporating 7-aminoheptanoic acid and an oligo-D-lysine motif.
• Evaluation of anticonvulsant and analgesic activity following intraperitoneal and oral administration in mouse models.

Main Results:

• Analogue D-Gal(7-Ahp)-B2 demonstrated anticonvulsant and analgesic activity after intraperitoneal administration.
• Oral administration of D-Gal(7-Ahp)-B2 showed significant analgesic effects in the mouse formalin model.
• Effective oral analgesic activity was observed at doses as low as 8 mg kg(-1) for both acute and inflammatory pain.

Conclusions:

• The modified galanin analogue D-Gal(7-Ahp)-B2 is orally active and possesses analgesic properties.
• This study presents a promising strategy for developing orally bioavailable peptide therapeutics for pain management.
• Further research may explore the full therapeutic potential of this class of compounds for neurological conditions.